First, although, the title suggests that patient had "Cushing's syndrome," the report does not mention any clinical or biochemical abnormalities suggestive of Cushing's syndrome except depression. Nonpsychiatric symptoms of Cushing's syndrome include central obesity, facial plethora, round face, purple striae, easy bruising of the skin, and muscle weakness. These symptoms are accompanied by clinical and biochemical signs of treatment-resistant hypertension, hyperglycemia, osteoporosis, hypokalemia, and nephrolithiasis. [2] Thus, the diagnosis of Cushing's syndrome, in this case, rests solely on laboratory evidence of hypercortisolemia. Authors have reported raised plasma cortisol (722.7 nmol/L, laboratory reference: 193-634 nmol/L). [1] Plasma cortisol has a well-defined circadian rhythm. Thus, it is important to mention the time at which sample was collected. Further, cortisol secretion increases during periods of stress like hospitalization and electro-convulsive therapy. For this reason, it is suggested that 24-h urinary free cortisol or midnight plasma cortisol should be used as a screening test for Cushing's syndrome. [2] Authors also report dexamethasone nonsuppression, which is a frequently used test to diagnose Cushing's syndrome. The case report does not mention the protocol of dexamethasone suppression test used in this case. Importantly, nonsuppression of cortisol levels with low-dose dexamethasone (1 mg) is expected in patients suffering from severe depression. [3] In such cases, a slightly cumbersome test which involves administration of 0.5 mg of dexamethasone at intervals of 6 h for 2 days and collection of two plasma samples is more appropriate. [2] Keeping in mind, that this patient also had an adrenal mass suggestive of adrenal adenoma, it falls in a difficult to diagnose category called subclinical Cushing's syndrome with an "Incidentaloma." [4] Second, authors report complete remission of depression with a combination of venlafaxine 300 mg/day and ketoconazole 400 mg/day. [1] There are important pharmacokinetic considerations involved in this combination. Venlafaxine is extensively metabolized to an active metabolite, desvenlafaxine mediated by cytochrome P 2D6 (CYP2D6). Venlafaxine and desvenlafaxine undergo transformation to inactive metabolites mediated by CYP3A4, CYP2C19, and CYP2C9. [5] Ketoconazole is a strong CYP 3A4 inhibitor. Thus, a clinically significant interaction between Venlafaxine and Ketoconazole is likely. The magnitude of this interaction depends on CYP2D6 activity. CYP2D6 activity depends on multiple genetic polymorphisms. Lindh et al. have reported that venlafaxine exposure is doubled when administered with ketoconazole in subjects who are CYP2D6 poor metabolizers. [6] At present, we do not have extensive data about CYP2D6 polymorphism in the Indian population, and poor metabolizers are reported at <1% frequency. [7] Nevertheless, clinicians need to consider this possibility. A patient who has low CYP2D6 activity and receives venlafaxine and ketoconazole will be exposed to toxic concentrations of Venlafaxine. This can present as a sympathomimetic syndrome, cardiovascular instability, and life-threatening cardiac arrhythmias. [8] Financial support and sponsorship Nil.
Sir, We are writing this letter to enlighten the readers of this journal about a novel and somewhat unresearched phenomenon with potential therapeutic applications.
Its name is Autonomous Sensor y Meridian Response (ASMR).
ASMR is a perceptual sensory phenomenon, likened to meditation, which encompasses a pleasant and calming "tingling" sensation localized to the scalp and neck in those able to experience it. [1] These sensations are triggered by specific auditory and visual stimuli such as whispering, personal attention, and even being the subject of a physician's clinical examination.
[1] People looking to experience ASMR turn to the website "YouTube" where videos have been produced that utilize these triggers. These videos are generally watched by users in a quiet environment to achieve the relaxing effect of ASMR. [1] Numerous media outlets have reported on ASMR; however, this phenomenon is not very well understood and our attempts to research ASMR on the database "PubMed" only provides three results (at the time of writing this article).
One of these papers was by Ahuja who described how this phenomenon can be caused by being the subject of a clinician's physical examination and suggests that ASMR may contribute to the therapeutic effects of a routine clinician's assessment. [2] Another paper was by Smith et al. and attempted to discover some of the neural underpinnings of ASMR, suggesting that individuals who experience ASMR demonstrate an increased connectivity between certain brain regions in the occipital, frontal, and temporal cortices. [3] The most clinically relevant paper is a study of 475 people who experience ASMR published by Barratt and Davis who show that ASMR helps users relax, deal with stress, and get to sleep with greater ease. [1] The authors also show that ASMR elicits a positive effect on mood and causes a significant reduction in symptoms of chronic pain for several hours following an ASMR session. [1] Given the prevalence of sleep disorders, anxiety, and depression in this day and age, it is important to explore every possible avenue with regard to therapeutics. It is obvious that research on this topic is still in its infancy and that publications in the field are few and far between. We also appreciate the difficulty in researching a phenomenon that can only be experienced by a small proportion of people
